
16 states sue over research grant cuts
Earlier this month, the NSF said it would no longer reimburse indirect costs for research exceeding 15 percent. The move comes after an April announcement that struck more than $200 million in funds for studies exploring Diversity, Equity, Inclusion, and Accessibility (DEIA) in addition to misinformation.
The coalition of states says that a federal law requires the NSF to increase the 'participation of women and underrepresented minorities' in science, technology, engineering, and math (STEM).
'This administration's attacks on basic science and essential efforts to ensure diversity in STEM will weaken our economy and our national security,' New York Attorney General Letitia James said in a statement on the lawsuit.
'Putting politics over science will only set our country back, and I will continue to fight to protect critical scientific research and education,' she added.
Alongside New York, California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Maryland, Massachusetts, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Wisconsin, and Washington are each listed as plaintiffs in the legal battle.
The NSF did not immediately respond to The Hill's request for comment on the legal challenge. The state's lawsuit comes as a group of 13 schools sued the NSF over slated changes.
'Research projects with more narrow impact limited to subgroups of people based on protected class or characteristics do not effectuate NSF priorities. NSF will continue to support research with the goal of understanding or addressing participation in STEM, in accordance with all applicable statutes and mandates, with the core goal of creating opportunities for all Americans,' the foundation wrote in an April statement.
'NSF will continue to support basic and use-inspired research in S&E fields that focus on protected characteristics when doing so is intrinsic to the research question and is aligned with Agency priorities,' it adds.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
BioAge (BIOA) to Analyze Over 17,000 Biobank Samples for Drug Discovery
BioAge Labs, Inc. (NASDAQ:BIOA) is one of the 11 Best New Penny Stocks to Buy Right Now. On June 17, BioAge Labs, Inc. (NASDAQ:BIOA) announced a new initiative to profile and analyze samples from the HUNT Biobank in Norway. The company will generate and analyze molecular profiles from more than 17,000 samples collected over decades of aging from more than 6,000 participants. BioAge Labs, Inc. (NASDAQ:BIOA) will use these samples to generate millions of molecular readouts. A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders. By carefully analyzing this data along with the health records of the participants, BioAge Labs, Inc. (NASDAQ:BIOA) aims to expand the proprietary human aging data that supports the company's drug-discovery platform. The company has exclusive rights to use this data for drug discovery. This initiative builds on the company's existing network of biobank partnerships. BioAge Labs, Inc. (NASDAQ:BIOA) expects this partnership to help accelerate its ability to find drug targets that maintain physiological resilience and help counter age-related disease. BioAge Labs, Inc. (NASDAQ:BIOA) is a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases by targeting the biology of human aging. While we acknowledge the potential of BIOA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
26 minutes ago
- Yahoo
Stifel Keeps Buy Rating on Alto Neuroscience (ANRO)
Alto Neuroscience, Inc. (NYSE:ANRO) is one of the 11 Best New Penny Stocks to Buy Right Now. On June 26, Stifel reiterated its 'Buy' rating on Alto Neuroscience, Inc. (NYSE:ANRO) with a price target of $10. This decision came after the company announced Phase 2 proof-of-concept results for its drug ALTO-203 in major depressive disorder (MDD) patients with elevated levels of anhedonia. A close-up of a healthcare professional in a lab coat, handling a pipette with medications for neuroscience diseases. The trial showed mixed results. However, Stifel analysts noted that ALTO-203 showed significant positive effects in improving sustained attention and increased wakefulness. The strongest results were seen in patients with more abnormal theta/beta EEG ratios at baseline, which is a biomarker that can be used to help diagnose ADHD. Stifel described the trial as exploratory with low expectations, noting that although this program keeps some options open for Alto Neuroscience, Inc. (NYSE:ANRO), it does not change the core investment view as the company prioritizes its late-stage pipeline. The next steps for ALTO-203 are yet to be determined. Alto Neuroscience, Inc. (NYSE:ANRO) is a clinical-stage biopharmaceutical company focused on the development of treatment options for neuropsychiatric disorders. While we acknowledge the potential of ANRO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
26 minutes ago
- Yahoo
Metagenomi (MGX) Presents Latest in Gene Editing Technologies
Metagenomi, Inc. (NASDAQ:MGX) is one of the 11 Best New Penny Stocks to Buy Right Now. On May 14, Metagenomi, Inc. (NASDAQ:MGX) announced that it is presenting three abstracts at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, held from May 13 to 17, 2025, in New Orleans, Louisiana. These presentations highlighted Metagenomi, Inc.'s (NASDAQ:MGX) advancements in compact nucleases for extrahepatic gene editing and CAST (CRISPR-associated transposases) for site-specific integration of large therapeutic genes. A lab scientist peering into a microscope focused on gene editing technology. The company's special metagenomics discovery platform can systematically identify and optimize novel gene editing systems through natural microbial evolution and AI-guided protein optimization. At the meeting, Metagenomi, Inc. (NASDAQ:MGX) shared early proof-of-concept data across different types of gene-editing technologies. This included compact Type II and Type V nucleases for efficient in vivo editing and a programmable Type V-K CAST system capable of targeted integration of large DNA cargoes. The small nucleases can potentially improve delivery to hard-to-reach tissues, while CAST offers promising new tools for targeted and precise large gene integration, addressing one of the greatest challenges in gene editing. Metagenomi, Inc.'s (NASDAQ:MGX) work shows promise in specifically integrating correct copies of complete genes, which could enable treatment for diseases caused by a loss-of-function mutation. Metagenomi, Inc. (NASDAQ:MGX) is a precision gene editing company focused on developing curative therapeutics using its proprietary, metagenomics-derived genome editing toolbox. While we acknowledge the potential of MGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data